Navigation Links
Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year
Date:2/12/2008

nd twelve

months ended December 31, 2007 both include a charge of $3.8 billion

in connection with the acquisition of OBS.

5/ Included in other income, net for the three months ended December 31,

2007 are $255 million of acquisition-related gains on currency-related

items. Included in other income, net for the twelve months ended

December 31, 2007 are $537 million of acquisition-related net gains on

currency-related and interest rate-related items.

6/ Special and acquisition related charges for the three and twelve

months ended December 31, 2007 reflect $52 million and $84 million,

respectively, related to the acquisition of OBS. Special and

acquisition related charges for the three and twelve months ended

December 31, 2006 are $12 million and $102 million, respectively,

reflecting charges related to the manufacturing changes announced June

1, 2006.

7/ In the first quarter of 2006, Schering-Plough adopted the provisions

of SFAS 123R. As a result of this adoption, Schering-Plough

recognized a non-recurring cumulative effect adjustment of $22 million

of income associated with Schering-Plough's liability-based

compensation plans.

SCHERING-PLOUGH CORPORATION

Reconciliation from Reported Net (Loss)/Income Available to Common Shareholders and Reported Diluted (Loss)/Earnings Per Common Share to As Reconciled Amounts for Net (Loss)/Income

Available to Common Shareholders and Diluted (Loss)/Earnings per Common Share (unaudited)

(Amounts in Millions, except per share figures)

To supplement its consolidated financial statements presented in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP"), Schering-Plough is providing the supplemental financial information below and on the following pages to reflect "As R
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

Related biology technology :

1. Schering-Plough and OraSure Technologies Sign International Collaboration for Rapid Point-of-Care Oral Hepatitis C Test
2. Schering-Plough Announces Organizational Changes at Schering-Plough Research Institute
3. FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
4. Schering-Plough Announces Sugammadex New Drug Application Filed in Japan
5. Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA
6. Schering-Plough to Webcast Presentation at Morgan Stanley Pharmaceutical CEOs Unplugged Conference
7. Schering-Plough Schedules Conference Call and Webcast for 2007 Fourth Quarter, Full-Year Financial Result
8. Schering-Plough Wins Three of Scrips Top Pharma Industry Awards
9. Schering-Plough Completes Acquisition of Organon BioSciences
10. Schering-Plough Receives Approval from European Commission for Planned Acquisition of Organon BioSciences N.V.
11. Schering-Plough to Webcast Presentation at Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/18/2009)...rsity Belfast are developing new sensors to detect... in the fight against the threat of terrorist atta...,swipe, an individual or crime scene to gather a s...ent that can detect the presence of chemicals with...ns to be made in response to terrorist threats. ,...
(Date:11/18/2009)...v. 18 Masimo (Nasdaq: ... Measure-Through Motion and Low-Perfusion pulse ox...i.H.A., one of the largest healthcare Group Purcha...ulti-year purchasing agreement for "gold standard"...t offers preferred contract pricing to Uni.H.A.,s ...
(Date:11/18/2009)...v. 18 /PRNewswire-FirstCall/ - YM BioSciences Inc....uct development company that identifies and advanc... products at various stages of development, announ...ab were presented today in a poster at the 2009 AA...tics conference in Boston, Massachusetts. The repo...
(Date:11/18/2009)...tly reduces key cardiac enzymes at multiple time p...rican Heart Association 2009 Scientific Sessions ,...rapeutics Inc., a biotechnology company pioneering...apeutics derived from pathogens, today reported re...T-111 (Serp-1), an anti-inflammatory protein deriv...
Breaking Biology Technology:New technology detects chemical weapons in seconds 2Uni.H.A. in France Signs Purchasing Agreement for Masimo SET(R) Pulse Oximetry Products 2Uni.H.A. in France Signs Purchasing Agreement for Masimo SET(R) Pulse Oximetry Products 3Uni.H.A. in France Signs Purchasing Agreement for Masimo SET(R) Pulse Oximetry Products 4YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB RESULTS IN ADVANCED TRIPLE-NEGATIVE BREAST CANCER MODEL PRESENTED AT AACR-NCI-EORTC MEETING 2YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB RESULTS IN ADVANCED TRIPLE-NEGATIVE BREAST CANCER MODEL PRESENTED AT AACR-NCI-EORTC MEETING 3Viron reports positive Phase II data in Acute Coronary Syndromes (ACS) patients 2Viron reports positive Phase II data in Acute Coronary Syndromes (ACS) patients 3Viron reports positive Phase II data in Acute Coronary Syndromes (ACS) patients 4
...,Corporation (NYSE: BSX ) today announced that it... Vascular Surgery businesses to the Getinge Group ...ws the definitive agreement,announced on November ... charges of approximately $240,million in connecti...orded,during the fourth quarter of 2007 and the fi...
...d,(Nasdaq: VICL ) today announced that Vijay Sama...rticipate in a panel discussion on biodefense and,...nnual JPMorgan Healthcare,Conference (San Francisc...by JP Morgan and McKenna, Long & Aldridge LLP.,Co-..., Former Special,Assistant to the President and Se...
...s,Inc. (Nasdaq: ANDS ) announced today that it wi...Conference on Thursday, January 10, 2008 at 11:00 ...held at the Westin St. Francis,Hotel in San Franci...xecutive Officer of Anadys,Pharmaceuticals, Inc., ...its two development-stage product candidates, ANA5...
Other Biology Technology:Boston Scientific Completes Sale of Cardiac Surgery and Vascular Surgery Businesses 2Boston Scientific Completes Sale of Cardiac Surgery and Vascular Surgery Businesses 3Vical to Participate in Pandemic Influenza Panel at JPMorgan Healthcare Conference 2Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference 2
(Date:11/20/2009)...x shives, and generated from Brassica carinata , ...ulf fields in spring, can be used to produce bioet...ied out by Spanish and Dutch researchers and publi...rgy Reviews . , "These studies evaluate, from an ...ethanol from two, as yet unexploited sources of bi...
(Date:11/19/2009)...with an unwieldy name: 4-hydroxybutyrate (4-HB). T...rape drug. , Now, a team of Ohio and Michigan s... is metabolized by the body. "This is new and impo...sor and chair of biological sciences at Michigan T...ch team. "It may provide new clues on how to coun...
(Date:11/19/2009)...es of the world. It is widely used for human consu...also is considered an exemplar plant species for s...nome architecture. The authors of the research pre...escription of the B73 maize genome to probe some o...ant biology. The ten papers consider maize centrom...
Breaking Biology News(10 mins):Flax and yellow flowers can produce bioethanol 2Researchers begin to decipher metabolism of sexual assault drug 2PLoS Genetics 2009 maize genome collection 2PLoS Genetics 2009 maize genome collection 3PLoS Genetics 2009 maize genome collection 4Invasive Fungal Infections in HSCT Recipients 3A Improving Outcomes Through Prevention and Treatment 59601 1Invasive Fungal Infections in HSCT Recipients 3A Improving Outcomes Through Prevention and Treatment 59601 2Bedazzled Bras Benefit Breastcancer org 59599 1Bedazzled Bras Benefit Breastcancer org 59599 2Nutrition 21 Announces Financial Results for Q4 of Fiscal 2009 and Full Year Fiscal 2009 14496 1Nutrition 21 Announces Financial Results for Q4 of Fiscal 2009 and Full Year Fiscal 2009 14496 2Nutrition 21 Announces Financial Results for Q4 of Fiscal 2009 and Full Year Fiscal 2009 14496 3Nutrition 21 Announces Financial Results for Q4 of Fiscal 2009 and Full Year Fiscal 2009 14496 4Nutrition 21 Announces Financial Results for Q4 of Fiscal 2009 and Full Year Fiscal 2009 14496 5Nutrition 21 Announces Financial Results for Q4 of Fiscal 2009 and Full Year Fiscal 2009 14496 6
...daq: AWRE ), a leading supplier of broadband tec...nancial results for its first quarter ended March ... 2009 were $4.6 million, a decrease of 22% compare..., , The Company reports its net income and basic ...h U.S. generally accepted accounting principles (G...
...nces Law Enforcement Information Sharing , , WALL...ulletin Board: BKYI), a leader in finger-based bio...olutions, today announced a strategic partnership ...ce and public safety data communications network f...ce, and public safety-related information. , , (L...
... Consortium Now Includes over 40 Agencies , , WA... Bulletin Board: BKYI), a leader in finger-based b... solutions, today announced a contract award from ...bileCop(R), BIO-key,s law enforcement mobile data ...cles, the department,s patrol deputies and investi...
Other Biology News:Aware, Inc. Reports First Quarter 2009 Financial Results 2Aware, Inc. Reports First Quarter 2009 Financial Results 3Aware, Inc. Reports First Quarter 2009 Financial Results 4Aware, Inc. Reports First Quarter 2009 Financial Results 5Aware, Inc. Reports First Quarter 2009 Financial Results 6BIO-key(R) Enters Strategic Partnership With Nlets 2BIO-key(R) Enters Strategic Partnership With Nlets 3Tulsa County Sheriff Selects BIO-key(R) Mobile Data System 2
Peptone from Sigma-Aldrich
SmartSpec 3000 Spectrophotometer from Bio-Rad
Propidium Iodide Staining Solution Solution from BD Biosciences Pharmingen
BD Biocoat Matrigel Matrix Thin Layer 35 mm Culture Dishes from BD Biosciences - Discovery Labware
Biology Products: